Kornimate/medical-research-clean huggingface dataset:
the influence of partial remission phase of type 1 diabetes on patient outcome

Conditions: Diabetes Mellitus Type 1; Remission of Type 1 Diabetes; Chronic Complications of Diabetes

Summary: natural course of diabetes mellitus involves gradual reduction of β cell mass within islets of langerhans in the pancreas. symptoms of diabetes present when the mass of insulin-producing cells reaches a point where insulin concentration does not suffice to maintain proper glycaemia. in many patients β cells regenerate shortly after the diagnosis of diabetes and initiation of insulin therapy. this phenomenon is called a remission. the aim of this study is to asses the influence of occurrence and duration of remission on development of chronic complications of diabetes and patients outcome.

natural course of diabetes mellitus involves gradual reduction of β cell mass within islets of langerhans in the pancreas. symptoms of diabetes present when the mass of insulin-producing cells reaches a point where insulin concentration does not suffice to maintain proper glycaemia. in many patients β cells regenerate shortly after the diagnosis of diabetes and initiation of insulin therapy. this phenomenon is called a remission. the aim of this study is to asses influence of occurrence and duration of remission on development of chronic complications of diabetes and patients outcome. clinical remission was defined as time in which all of the following criteria were met: hba1c below 6.5 % , dose of exogenous insulin below 0.3 u / kg body weight and serum c-peptide concentration above 0.5 ng / ml. patients were divided into those who were in remission at any time during follow-up (remitters) and non-remitters. at follow-up occurrence of chronic microvascular complications of diabetes (retinopathy, diabetic kidney disease and neuropathy) was evaluated.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed type 1 diabetes according to ada (american diabetes association) 1997 criteria. 2. age 18-35 years 3. education with regard to intensive functional insulin therapy at the time of diagnosis 4. patient consent to participation in the study exclusion criteria: 1. acute inflammation (serum c-reactive protein concentration (hscrp) \>10mg/l, leukocytosis \>15x109/l, erythrocyte sedimentation rate (ob) \>30 mm/h) 2. laboratory signs of liver damage: alanine and aspartate aminotransferase elevated 2-fold over the upper limit of normal range 3. history of other chronic diseases (e.g. asthma, neoplastic diseases, liver cirrhosis) 4. other autoimmunological diseases other than diabetes 5. not confirming type 1 diabetes after obtaining results of autoantibodies

Keywords: diabetes mellitus type 1 remission, honeymoon microangiopathy
effect of tachosil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer.

Conditions: Prostate or Bladder Cancer

Summary: pelvic lymph node dissection (plnd) is the most accurate staging tool to determine lymph node involvement in prostate and bladder cancer. the main complication of plnd is development of a lymphocele, which can cause symptoms including lower abdominal pain, leg or penile/scrotal edema, bladder outlet obstruction, deep venous thrombosis or infection/sepsis. the incidence of radiographic (asymptomatic) and symptomatic lymphoceles following plnd varies between 12,6-63% and 1,6-33% respectively. medicated sponges such as tachosil® are indicated in surgery for improvement of haemostasis and to promote tissue sealing. they could reduce lymphocele development by increased tissue sealing, due to a mechanical effect of the sponge itself and a lymphostatic effect of the included thrombin and fibrinogen. our goal is to prospectively assess the lymphostatic effect of tachosil(r) in patients undergoing transperitoneal plnd with or without radical prostatectomy or plnd with bladder cancer surgery.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * diagnosis of prostate cancer or bladder cancer on pathology * undergoing transperitoneal pelvic lymph node dissection. exclusion criteria: * previous pelvic surgery or irradiation. * any type of clotting disorder.

Keywords: patients, undergoing pelvic lymph node dissection.
anti-inflammatory status in dm2 treated patients

Conditions: Diabetes Mellitus, Type 2

Summary: diabetes mellitus type 2 (dmt2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of fatty streaks and atherosclerotic plaques. atherosclerosis accounts for more than 600,000 deaths annually in the u.s. mainly due to acute myocardial infarction and stroke. pharmacological therapy of dmt2 includes several drugs used as monotherapy, although combination therapy between metfomin plus thiazolidinediones (tzd) and/or dipeptidyl-peptidase 4 inhibitors (dpp4i) plus tdz, may delay atherosclerosis progression even if the molecular mechanisms are not clear. even if normoglycemia is achieved, dmt2 patients still displayed a higher risk for developing atherosclerosis suggesting that other mechanisms of the inflammatory status are involved

diabetes mellitus type 2 (dmt2) - a progressive insulin secretory defect on the background of insulin resistance - is one of the major risk factors for atherosclerosis, an inflammatory disease of the arterial wall, in which leukocytes and oxidized lipoproteins accumulate leading to formation of fatty streaks and atherosclerotic plaques. atherosclerosis accounts for more than 600,000 deaths annually in the u.s. mainly due to acute myocardial infarction and stroke. pharmacological therapy of dmt2 includes several drugs used as monotherapy, although combination therapy between metfomin plus thiazolidinediones (tzd) and/or dipeptidyl-peptidase 4 inhibitors (dpp4i) plus tdz, may delay atherosclerosis progression even if the molecular mechanisms are not clear . even if normoglycemia is achieved, dmt2 patients still displayed a higher risk for developing atherosclerosis suggesting that other mechanisms of the inflammatory status are involved

Eligibility criteria:
inclusion criteria: * dmt2 patients were enrolled in presence of 1. age \>35 and \<75 years old 2. uncontrolled diabetes during treatment (glycosylated hemoglobin (hba1c) \> 75 mmol/mol ) 3. combined therapy at least by 6 months. exclusion criteria: 1. hba1c \< 75 mmol/mol (9%); 2. history of drug abuse or alcohol abuse, averaging more than 30 gm/day (3 drinks per day) in the previous 10 years, or history of alcohol intake averaging greater than 10 gm/day (1 drink per day: 7 drinks per week) in the previous one year; 3. estimated glomerular filtration rate (gfr) \<30 ml/min (according to mdrd formula) 4. .liver failure 5. recent history of heart stroke, systemic infections, dehydration, lactic acidosis 6. heart failure (nyha i - iv) 7. active bladder cancer or history of bladder cancer 8. macroscopic haematuria of unidentified nature 9. hypersensitivity to drug used (metformin, alogliptin, pioglitazone) 10. breastfeeding
efficacy and safety evaluation of pneumostem® versus a control group for treatment of bpd in premature infants

Conditions: Bronchopulmonary Dysplasia

Summary: the objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of pneumostem® for treatment of bronchopulmonary dysplasia (bpd) in high-risk premature infants by comparing pneumostem-treated group with a control group.


Eligibility criteria:
inclusion criteria: * age: 5 - 14 days since birth * fetal gestational age: ≥23 weeks and \<29 weeks * birth weight: ≥500g and ≤1250g * premature infant of equal to or less than 2 weeks of age who is receiving a ventilator therapy at a rate of \> 12 breath/min and \> 25% oxygen * patient whose ventilator setting has not been changed and who has shown aggravation of the illness within the 24 hours prior to the study enrollment * patient with a written consent form signed by a legal representative or a parent upon explanation of the clinical trial exclusion criteria: * patient with concurrent cyanotic or acyanotic congenital heart diseases, except for patent ductus arteriosus * patient with a concurrent severe lung malformation (i.e. pulmonary hypoplasia, congenital diaphragmatic hernia, congenital cystic lung disease) * patient with a concurrent severe lung malformation with chromosome anomalies (i.e. edward syndrome, patau syndrome, down syndrome, etc) or severe congenital malformation (hydrocephalus, encephalocele, etc) * patient with a concurrent severe congenital infection (i.e. herpes, toxoplasmosis, rubella, syphilis, aids, etc) * patient withcrp \> 30 mg/dl; severe sepsis or shock * patient who is scheduled for or expected to undergo a surgical procedure 72 hours prior to/following the administration of the study drug * patient who has been administered with a surfactant within the 24 hours prior to the administration of the study drug * patient with severe intracranial hemorrhage ≥ grade 3 or 4 * patient with active pulmonary hemorrhage or active air leak syndrome at the time of screening * patient with a history of participating in other clinical studies * patient who is allergic to gentamicin * patient who is considered inappropriate to participate in the study by the investigator

Keywords: human umbilical cord blood derived mesenchymal stem cells bronchopulmonary dysplasia premature infants
cyberknife for prostate cancer patients aged 70 y or more

Conditions: Prostate Cancer

Summary: robotic stereotactic radiation treatment of prostatic adenocarcinoma of the elderly. inclusion criteria : t1-t3b, mri pelvic nodes negative, m0, any gleason score, psa (prostate specific antigen) \<30ng/ml. dose : 36.25 gy in 5 fractions, in 10 days, considering capra scores≤5 and 37.5 gy in 5 fractions, in 10 days, considering capra scores\>5. primary objective : acute and late toxicity evaluation at 36 months. secondary objectives : psa and mri response.

robotic stereotactic radiation treatment of prostatic adenocarcinoma of the elderly. rationale : half of the prostatic adenocarcinoma are diagnosed in the elderly but until now curative treatments were not proven to increase overall survival rates. therefore, very short, comfortable and safe treatments have to be designed to increase the pelvic control of the disease. moreover, the alpha/beta ratio of the disease ≤3gray is in favour of using hypofractionation schemes. primary objective : acute and late toxicity evaluation at 36 months. secondary objectives : psa and mri response and quality of life evaluation. inclusion criteria : t1-t3b, mri pelvic nodes negative, m0, any gleason score, psa\<30ng/ml. dose : 36.25 gray in 5 fractions, in 10 days, considering capra score≤5 and 37.5 gray in 5 fractions, in 10 days, considering capra scores\>5. doses to the organs at risk (oar) : rectum wall : v36.25\<2%, v27\<20%, v23\<30%, v20\<35%. bladder wall : v36.25\<2%, v27\<20%, v20\<35%. considering specifically the prescription of 37.5 gray, the rectum and bladder wall: v37.5\<2%. anytime, hot spots of 105 % of the prescription dose must avoid the urethra. evaluation criteria : ctcaev4 (common toxicity criteria for adverse events, version4), psa, multiparametric mri, ipss (international prostate score symptom) and iief5 (international index of erectile function). methodolgy : this is a three step prospective, observational study of 20 patients each step. before moving to the next step, the severe acute or late toxicity at a median follow-up of 1 year must remain below 5% each.

Eligibility criteria:
inclusion criteria: * t1-t3b, * mri pelvic nodes negative, * m0, * any gleason score, * psa\<30ng/ml, * who (world health organisation) score\<2, ipss≤15, * maximal urinary flow rate ≥15ml/s, * mean urinary flow rate ≥5ml/s, * multiparametric prostatic and pelvis mri exclusion criteria: * prostatic volume \> 100cc, * turp (transurethral prostatectomy) \<3 y, * any recurrent prostatitis within the last 3 years, * collagenose diseases, * ulcero-haemorrhagic rectocolitis or * crohn diseases

Keywords: prostate cancer radiation stereotactic cyberknife elderly
efficacy of artemisia pollen specific allergen immunotherapy

Conditions: Allergic Rhinitis

Summary: allergic rhinitis (ar) is a noninfectious inflammatory disease of the nasal mucosa mediated by immunoglobulin e (ige) after exposure to allergens. artemisia annua is one of the most important allergen that is responsible for seasonal ar in china during july and october. allergen specific immunotherapy (ait) is the only etiological treatment available for ar. the trial is a randomized, open label, multicentred trial. a total of 150 subjects with allergic rhinitis caused by artemisia pollen were recruited and randomized to the immunotherapy group and conversation drugs group.


Eligibility criteria:
inclusion criteria: * presence of seasonal rhinitis symptoms. * the tnss was higher than 6 scores in last autumn pollen season. * artemisia-specific immunoglobulin e (ige) levels (immunocap) at least class 3, and higher than both of ragweed and humulus ige levels. * patients who have been informed of the nature and aims of the study and have given their written consent, willing to comply with the protocol. * patients who are able to understand the information given and the consent and complete the daily record card. exclusion criteria: * ulcers, inflammation or trauma in the sublingual part; * oral diseases / oral allergies; * had surgery within four weeks before screening evaluation; * continuous use of systemic glucocorticoids within four weeks before screening evaluation; * any history of severe systemic allergic reaction and eosinophilic esophagitis before screening evaluation; * suffering from perennial allergic rhinitis; * complicated with chronic rhinitis or sinusitis, nasal polyps; * in the recent pollen season, rhinitis can be relieved without symptomatic treatment; * within 2 years before enrollment, diagnosed with a history of moderate and severe asthma or fev1 less than 70% of the estimated value; * applying β treatment with receptor blockers (including systemic and local drugs) or angiotensin converting enzyme (ace) inhibitors; * participated in clinical trials of other drugs within one month; receiving other pollen allergen specific immunotherapy; * pregnant and lactating women or those who have pregnancy planning within the past year; * history of immunosuppressive disease (such as hiv infection history), history of malignancy, history of autoimmune diseases, history of pulmonary tuberculosis, cardiovascular dysfunction, or other serious diseases of other organ systems judged by researchers. * received pollen allergen specific immunotherapy or are receiving allergen specific immunotherapy within three years.
transrectal evaluation after discoid resection for endometriosis intestinal

Conditions: Deep Endometriosis

Summary: evaluating the success of rectosigmoidoscopy performed after intestinal resection in women with deep endometriosis during surgery

endometriosis is an inflammatory, benign, oestrogen-dependent condition that affects 10-15% of women of reproductive age. it is characterised by the presence of endometrial tissue, glands and stroma, outside the uterine cavity. endometriosis may present in the pelvis as superficial peritoneal, ovarian or deep infiltrating. the reported prevalence of bowel or recto-vaginal space involvement among women with endometriosis ranges from 5% to 25% (2). surgery is the treatment of choice for deep endometriosis with bowel involvement when drug therapy alone is ineffective in treating symptoms. surgical techniques for intestinal endometriosis can be divided into full-thickness techniques (discoid or segmental resection) and non-full-thickness techniques (shaving). focusing on women who underwent a discoid resection, 3.7% of 80 reported a recto-vaginal fistula and the same percentage showed early rectorrhagia requiring endoscopic treatment after surgery. in general surgery rectosigmoidoscopy has shown encouraging results as a feasible, safe and effective technique in reducing the risk of complications related to intestinal anastomosis. there are no studies in the literature evaluating the role of rectosigmoidoscopy as a routine practice in gynaecological surgery for endometriosis, so we rely on the experience of general surgeons. in particular, the lack of data does not allow us to evaluate the feasibility of rectosigmoidoscopy during deep endometriosis surgery in terms of the success of the procedure itself and the additional operative time taken. the latter aspect is also important from the point of view of health policy due to the increased cost of the operating theatre directly related to the time taken for the procedure.

Eligibility criteria:
inclusion criteria: * women between the ages of 18 and 50 years * women with diagnosis made by instrumental examination such as transvaginal ultrasound, of deep endometriosis with suspected bowel involvement * women undergoing segmental or discoid resection for bowel endometriosis * obtaining informed consent exclusion criteria: * patients who are candidates for elective laparotomic surgery * patients with concomitant inflammatory bowel disease known in history (inflammatory bowel syndrome)

Keywords: endometriosis discoid resection deep endometriosis intestinal
assessment of visual dyslexia remediation protocols - dyslexia remediation

Conditions: Dyslexia

Summary: dyslexia is first described as a phonological deficit. several studies report a neurovisual deficit in dyslexics. some dyslexics have a visual deficit without phonological impairment, others have a pure phonological deficit, and still others have both types of deficits. from this observation the idea emerged to propose specific remediation protocols for people with visual impairments and to assess their effects on reading. at the theoretical level, if visual stimulation is able to improve reading performance, it is the demonstration of the existence of visual origin of dyslexia. at the clinical level, such a result not only opens the prospect of a different and more adapted rehabilitation for these types of dyslexia, but also the prospect, if the visual deficits are pre-existing to the learning of reading, to use them for early diagnosis and management.


Eligibility criteria:
inclusion criteria: * male or female * aged 8 to 12 * diagnosed dyslexics * normal or corrected to normal vision * legal guardians of children subjects providing their free, informed and written consent to participate in the study; with the child also giving orally his consent to participate. exclusion criteria: * other neurodevelopmental problem * strabismus, amblyopia for the glasses (group 2) : epileptic child are excluded

Keywords: dyslexia remediation visual attention span visual search
effect of osteopathic manipulative treatment on length of stay in preterms

Conditions: Prematurity

Summary: the use of osteopathic manipulative treatment (omt) in preterm infants has been documented and results from previous studies suggest the association between omt and length of stay (los) reduction, as well as significant improvement in several clinical outcomes. the aim of the present study is to show the effect of omt on los in a sample of premature infants.


Eligibility criteria:
inclusion criteria: * preterm infants born at age between 29 and 37 weeks * osteopathic treatment performed \< 14 days after birth * preterms born in the same hospital exclusion criteria: * gestational age \ 37 weeks; * osteopathic treatment performed \> 14 days after birth; * newborn transferred to/from other hospital; * newborn from to hiv seropositive and/or drug addict mother; * newborn with genetic disorders, congenital abnormalities, cardiovascular abnormalities, neurological disorders, proven or suspected necrotizing enterocolitis with or without gastrointestinal perforation, proven or suspected abdominal obstruction, pre- and/or post-surgery patients, pneumoperitoneum and/or atelectasis.

Keywords: osteopathic manipulative treatment alternative medicine complementary medicine neonatology neonatal care prematurity allied health care
pterygium treatment using single beta-therapy as adjuvant treatment compared to conjunctival autograft

Conditions: Pterygium

Summary: purpose: to affirm the effectiveness and complication rate of postoperative single-dose beta-irradiation (rt) with (90) sr in the case of primary pterygium in a clinical trial. methods and materials: this trial was designed as a prospective, randomized, single center study. surgery was performed in all cases according to the conjunctival autograft technique. one thousand and four patients with 108 pterygia were postoperatively randomized to either beta-rt or observation. in the case of beta-rt, a (90) sr eye applicator was used to deliver 1000 cgy to the sclera surface at a dose rate of between 200 and 250 cgy/min. after treatment, both an ophthalmologist and a radiation oncologist performed the follow-up examinations. the accumulated data were analyzed using a group sequential test. results: between february 2007 and september 2008, 104 eyes with primary pterygium were operated on according to the trial protocol. additional treatment was performed within 24 hours postoperatively. four patients were lost to follow-up, resulting in 104 patients who could be analyzed. in the 54 eyes randomized to receive beta-rt, 5 relapses occurred compared with 8 recurrences in the 50 eyes that no received rt, for a crude control rate of 90.7 % vs. 84 %, respectively. at a mean follow-up of 9 months (range 4- 18), major treatment complications had not been observed . conclusion: single-dose beta-rt of 1000cgy after conjunctival autograft surgery is a simple, effective, and safe treatment that reduces the risk of primary pterygium recurrence.


Eligibility criteria:
inclusion criteria: * fresh pterygium without previous treatment. * adult patients with age higher than 18 years. exclusion criteria: * diagnosis of glaucoma. * previous treatment of pterygium. * patients with age less than 18 years old.

Keywords: beta-irradiation;conjunctival autograft;pterygium;recurrence; clinical trial